Catherine Park

Catherine C. Park, M.D.

Professor and Chair

Department of Radiation Oncology

University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
Box 1708,1600 Divisadero St, H1031
San Francisco, CA 94115
Phone: 415 353-7175
Fax: 415 353-9883

Research Website

 

Professional Focus

Dr. Catherine Park is a radiation oncologist with a special interest in the treatment of lymphoma and breast cancer. She earned a medical degree at the UCLA School of Medicine and completed a residency in radiation oncology at the Joint Center for Radiation Oncology at Harvard Medical School. After serving as a visiting scientist at the Lawrence Berkeley National Laboratory, Dr. Park joined UCSF Medical Center.

She is the recipient of numerous awards, including the Upjohn Achievement Award and C. Donald O'Malley Prize in the History of Medicine.

Education

1989 University of California, Berkeley BA History of Art
1995 UCLA MD  
1995-1996 Beth Israel Hospital, Harvard Medical School Intern  
1996-2000 Joint Center for Radiation Therapy, Harvard Medical School Resident  
1998-1999 Lawrence Berkeley National Laboratory Research Fellow  

 

Professional Experience

2014-present UCSF Professor in Residence Radiation Oncology
2006-present Lawrence Berkeley National Laboratory Faculty Biologist Division of Life Sciences
2008-2014 UCSF Associate Professor in Residence Radiation Oncology
2005-2008 UCSF Assistant Professor in Residence Radiation Oncology
2000-2005 UCSF Assistant Clinical Professor Radiation Oncology
2000-2006 Lawrence Berkeley National Laboratory Visiting Scientist Division of Life Sciences

 

Awards & Honors

1995 Alpha Omega Alpha
1995 AMWA Janet M. Glasgow Memorial Achievement Citation
1995 C. Donald O'Malley Prize in the History of Medicine
1995 Dean's Scholar, Thesis Program UCLA School of Medicine
1995 Upjohn Achievement Award for Excellence in Research
2002 Career Development Award, Breast SPORE, UCSF
2002 Junior Investigator Award, International Society for Differentiation, Lyon, France
2003 Junior Investigator Award, European Society for Therapeutic Radiation Oncology, Copenhagen, DK
2003 Basic Science Junior Investigator Award, American Society for Therapeutic Radiation Oncology, Salt Lake City, UT
2003 Junior Faculty Award, AACR Clinical Protocol Workshop, Vail, CO
2005 Association of American Medical Colleges Early Career Faculty Womens Professional Development Seminar, Santa Fe, NM

 

Recent Significant Publications :

Park CC, Georgescu W, Polyzos A, Pham C, Ahmed KM, Zhang H, Costes SV. Rapid and automated multidimensional fluorescence microscopy profiling of 3D human breast cultures. Integr Biol (Camb). 2013 Apr 25;5(4):681-91.

Peled AW, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg. 2012 Sep;130(3):503-9.

Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31;13(4):R84.

Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRIIntegr Biol (Camb). 2011 Apr;3(4):490-6.

Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res. 2010 Jul 1;70(13):5238-48.

Park CC, Yom SS, Podgorsak MB, Harris E, Price RA Jr, Bevan A, Pouliot J, Konski AA, Wallner PE; Electronic Brachytherapy Working Group. American Society for Therapeutic Radiology and Oncology (ASTRO) Emerging Technology Committee report on electronic brachytherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):963-72.

Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010 Jul;122(1):35-43.